There are two different approaches to Nanotechnology in Drug Delivery, making drug crystals smaller to increase solubility and bioavailability, or using some form of carrier to deliver them in a more effective manner.
If we look at the total market size in 2021, it is a 60/40 split in favour of drug nano crystals although we feel that developing new delivery mechanisms may allow more value to be created.
The best performing nano carriers are shaping up to be:
- Liposomes (28%);
- Gold Nanocarriers (17%);
- Dendrimers (17%);
- Micelles (11%);
- Polymer-based Nanocarriers (5%);
- Nanoshells (2%);
- Ceramic Nanocarriers (<1%);
- Calcium phosphate Nanocarriers (<1%).
Cientifica Ltd published Nanotechnology in Drug Delivery 2011 on 2 November 2011. Here’s a few of the key findings.
MARKET ANALYSIS BY KEY TECHNOLOGY
Of All Key Technologies Studied…
An analysis of the Total Addressable Market (TAM) in 2010, for nanotechnology in drug delivery (NDD), all key technologies studied shows the following values in 2010 (by descending order):
- Drug Nanocrystals (596 US$ Million Dollars), (45%);
- Total Nanocarriers (434 US$ Million Dollars), (32%);
- Targeted Delivery (178 US$ Million Dollars), (13%);
- Solubility + Bioavailability (139 US$ Million Dollars), (10%).
Nanocarriers as a Whole…
An analysis of the TAM in 2010, for NDD, nanocarriers as a whole shows the top 5 nanocarriers TAM values in 2010 as follows (by descending order):
- Liposomes (118 US$ Million Dollars), (28%);
- Dendrimers (84 US$ Million Dollars), (19%);
- Micelles (63 US$ Million Dollars), (15%);
- Gold Nanocarriers (56 US$ Million Dollars), (13%);
- CNTs (56 US$ Million Dollars), (13%).
Nanocarriers Versus Drug Nanocrystals…
Regarding total nanocarriers versus drug nanocrystals, drug nanocrystals show a higher TAM value in 2010, when compared with total nanocarriers:
- Drug Nanocrystals (596 US$ Million Dollars), (58%);
- Total Nanocarriers (434 US$ Million Dollars), (42%).
So, how advanced is NDD now? Which trends are being designed to 2021? Where will be opportunities for investment? Reading Nanotechnology in Drug Delivery 2011 will answer to these questions and many more and explain why?
At last weeks Nanotechnology for High performance Motorsport meeting, one of the participants, from a Formula One team, commented that he thought the current FIA regulations precluded the use of nanomaterials.
A bit of digging around in the current regulations (thanks to Chris Walker for unearthing this) only finds the following prohibition on using carbon nanotubes incorporated within carbon fibres, although given the difficulty of making an accurate distinction between nanotubes, nanofibres and carbon fibre it would be interesting to know which definition the is FIA using.
Carbon fibres manufactured from polyacrylonitrile (PAN) precursor which have :
- a tensile modulus ? 550GPa ;
- a density ? 1.92 g/cm3 ;
- unidirectional or planar reinforcement within their pre-impregnated form, not including three dimensional weaves or stitched fabrics (but fibre reinforcement using Z-pinning technology is permitted) ;
- no carbon nanotubes incorporated within the fibre or its matrix ;
- a permitted matrix, not including a carbon matrix.
As far as I know, nanotechnology was used in the 2009 season, with McLarens KERS system using A123s nano phosphate lithium ion batteries as a result of their combination of weight and charge/discharge capacity. It certainly seems that other than the specific regulation above, there are no limits to what can be applied, and the ingenuity of motorsport engineers is second to none.
Of course were anyone except Ferrari to gain a substantial technical advantage from nanotechnology we may see the regulations being tweaked, but in general this is done to close loopholes that the use of novel materials may allow engineers to exploit, rather than to ban a whole technology.
Technology Review has a piece on Unidym’s conducting nanotube films and how they are about to hit the market.
Given the recent news about consolidation, and cash problems, that market can’t come too soon.
More nanomaterials woes, this time from Unidym who you may recall bought Carbon Nanotechnology Inc’s and CSixty’s IP for a song a few years ago. We’ve herard of big job cuts and this comes from the annual report of their parent, Arrowhead Research Corporation. It can be read along the lines of desperate cash starved company mortgages its future to Tokyo Electron in exchange for a couple of million bucks.
Unidym raised a total of $14 million of equity financing in fiscal 2008. In fiscal 2008, Unidym consumed large amounts of cash to scale up the manufacture of carbon nanotubes, scale up for the production and sale its first carbon nanotube based film product, acquire another nanotech company, expand its business development activities, and prepare for an initial public offering. In the first and second quarters of fiscal 2008, Unidym expanded its executive, technical and administrative staff for these activities. Unidym’s cash burn ramped from $2 million in the second quarter, $3.6 million in the third quarter and $4.2 million in the fourth quarter.
In the fourth quarter, it was clear that Unidym would be unable to meet its fund raising goals to support its 2009 cash needs. Moreover, technical development took longer than expected. Additionally, it became evident that dramatic change in the financial market would not allow an initial public offering. Starting in October 2008, several general and administrative positions were eliminated. Approximately, half of its team in its Houston, TX facility was put on unpaid leave to conserve cash. Further cuts to personnel and consolidation of facilities are planned to bring Unidym’s cash burn to 60% of its high water mark in fourth quarter 2008. However, Unidym will still need to obtain additional cash to fund its operations and obligations through fiscal 2009.
What is particularly depressing about this story is that the IP in question all came from the lab of Richard Smalley, one of the founding fathers of nanotechnology. So far it’s taken some $40 million to get, erm, nowhere. One day I’ll get around to adding up all the money spent on taking nanomaterials to market, it must be close to half a billion by now.

